Valeant Pharmaceuticals' shareholders just can't catch a break.
The drugmaker's stock traded in the single digits earlier on Wednesday for the first time since 2008 after falling more than 5 percent. The stock hovered around $9.60, far from a 52-week intraday high of $38.50 reached in May 2016, before closing down over 6 percent at $9.50 on Wednesday.
The latest dip came after reports surfaced that the firm was having a difficult time selling one of its divisions — its
Just last month, billionaire hedge fund manager Bill Ackman
As of Wednesday's close, Valeant's stock is down more than 66 percent over the past 12 months and is down more than 34 percent year-to-date.